JP2020090508A5 - - Google Patents

Download PDF

Info

Publication number
JP2020090508A5
JP2020090508A5 JP2020003665A JP2020003665A JP2020090508A5 JP 2020090508 A5 JP2020090508 A5 JP 2020090508A5 JP 2020003665 A JP2020003665 A JP 2020003665A JP 2020003665 A JP2020003665 A JP 2020003665A JP 2020090508 A5 JP2020090508 A5 JP 2020090508A5
Authority
JP
Japan
Prior art keywords
acid
pharmaceutical composition
dgla
composition according
atopic dermatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2020003665A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020090508A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2020090508A publication Critical patent/JP2020090508A/ja
Publication of JP2020090508A5 publication Critical patent/JP2020090508A5/ja
Priority to JP2022030554A priority Critical patent/JP2022071061A/ja
Withdrawn legal-status Critical Current

Links

JP2020003665A 2014-06-04 2020-01-14 Dglaを含む薬学的組成物及びその使用 Withdrawn JP2020090508A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022030554A JP2022071061A (ja) 2014-06-04 2022-03-01 Dglaを含む薬学的組成物及びその使用

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462007752P 2014-06-04 2014-06-04
US62/007,752 2014-06-04
US201462058469P 2014-10-01 2014-10-01
US62/058,469 2014-10-01

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2016570986A Division JP2017516823A (ja) 2014-06-04 2015-06-04 Dglaを含む薬学的組成物及びその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022030554A Division JP2022071061A (ja) 2014-06-04 2022-03-01 Dglaを含む薬学的組成物及びその使用

Publications (2)

Publication Number Publication Date
JP2020090508A JP2020090508A (ja) 2020-06-11
JP2020090508A5 true JP2020090508A5 (https=) 2020-07-30

Family

ID=53298373

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016570986A Pending JP2017516823A (ja) 2014-06-04 2015-06-04 Dglaを含む薬学的組成物及びその使用
JP2020003665A Withdrawn JP2020090508A (ja) 2014-06-04 2020-01-14 Dglaを含む薬学的組成物及びその使用
JP2022030554A Pending JP2022071061A (ja) 2014-06-04 2022-03-01 Dglaを含む薬学的組成物及びその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016570986A Pending JP2017516823A (ja) 2014-06-04 2015-06-04 Dglaを含む薬学的組成物及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022030554A Pending JP2022071061A (ja) 2014-06-04 2022-03-01 Dglaを含む薬学的組成物及びその使用

Country Status (17)

Country Link
US (9) US9682055B2 (https=)
EP (2) EP3692986A1 (https=)
JP (3) JP2017516823A (https=)
KR (1) KR102391827B1 (https=)
CN (1) CN107072959A (https=)
AU (2) AU2015270418B2 (https=)
BR (1) BR112016028518A2 (https=)
CA (1) CA2953633A1 (https=)
ES (1) ES2784240T3 (https=)
IL (2) IL249364B (https=)
MA (1) MA52644A (https=)
MX (2) MX375328B (https=)
PH (1) PH12016502530A1 (https=)
RU (2) RU2020101477A (https=)
SG (2) SG11201610207WA (https=)
WO (1) WO2015185698A1 (https=)
ZA (2) ZA201708681B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
EP3068757B1 (en) 2013-11-15 2019-02-27 DS Biopharma Limited Lysine salt of 15-hydroxy-8(z),11(z),13(e)-eicosatrienoic acid
ES2784240T3 (es) * 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
CN117402059A (zh) 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
EP3399971A1 (en) * 2016-01-07 2018-11-14 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
EP3624787A1 (en) * 2017-05-19 2020-03-25 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same
JP7500037B2 (ja) * 2019-07-24 2024-06-17 国立大学法人 東京大学 血中尿酸値低下剤及び血中尿酸値低下用食品組成物
US20210315851A1 (en) 2020-04-03 2021-10-14 Afimmune Limited Compositions comprising 15-hepe and methods of treating or preventing hematologic disorders, and/or related diseases

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5264452A (en) 1975-11-18 1977-05-27 Nippon Suisan Kaisha Ltd Method of producing processed fish meat
JPS5820575B2 (ja) 1975-11-27 1983-04-23 日本水産株式会社 スイサンカコウヒンノセイゾウホウ
US4273763A (en) 1978-01-23 1981-06-16 Efamol Limited Pharmaceutical and dietary compositions
IE47777B1 (en) * 1978-01-23 1984-06-13 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
US4444755A (en) 1978-01-23 1984-04-24 Efamol Limited Treatment for skin disorders
DE2967049D1 (en) 1978-04-11 1984-07-19 Efamol Ltd Pharmaceutical and dietary composition comprising gamma-linolenic acids
IE49783B1 (en) 1979-05-18 1985-12-11 Efamol Ltd Pharmaceutical and dietary composition comprising epsilon-linolenic acids
IE51145B1 (en) 1980-03-07 1986-10-15 Efamol Ltd Pharmaceutical and dietary compositions
IE53332B1 (en) 1980-03-14 1988-10-26 Efamol Ltd Pharmaceutical compositions
US5324748A (en) 1981-07-14 1994-06-28 Efamol Limited Method for enhancement of 1-series PG production
EP0087865B1 (en) 1982-03-01 1986-10-01 Efamol Limited Pharmaceutical composition
EP0087863B1 (en) 1982-03-01 1986-05-21 Efamol Limited Pharmaceutical and dietary composition
ATE22804T1 (de) 1982-03-01 1986-11-15 Efamol Ltd Pharmazeutische zusammensetzung.
ATE22533T1 (de) 1982-04-29 1986-10-15 Efamol Ltd Pharmazeutische zusammensetzung.
GB8302708D0 (en) 1983-02-01 1983-03-02 Efamol Ltd Pharmaceutical and dietary composition
GB8319073D0 (en) 1983-07-14 1983-08-17 Efamol Ltd Fatty acid compositions
GB8326130D0 (en) 1983-09-29 1983-11-02 Efamol Ltd Topical preparations containing tars and fatty acids
GB8420771D0 (en) 1984-08-15 1984-09-19 Efamol Ltd Treatment of skin disorders
GB8425006D0 (en) 1984-10-03 1984-11-07 Efamol Ltd Composition of copper/fatty acids
GB8506027D0 (en) 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
GB8522670D0 (en) 1985-09-13 1985-10-16 Efamol Ltd Drug treatments
GB8524275D0 (en) * 1985-10-02 1985-11-06 Efamol Ltd Pharmaceutical & dietary compositions
US5198468A (en) 1987-06-24 1993-03-30 Efamol Holdings Plc Essential fatty acid composition
EP0309086A1 (en) 1987-09-07 1989-03-29 Efamol Holdings Plc Treatment of male pattern baldness and of unwanted hair growth
GB8729153D0 (en) 1987-12-14 1988-01-27 Efamol Ltd Fatty acid compositions
JPH04507397A (ja) 1988-01-14 1992-12-24 フリッツ,アンデルス 湿疹治療用薬剤製造における必須脂肪酸の使用法
GB8806737D0 (en) 1988-03-22 1988-04-20 Efamol Holdings Therapeutic composition & method
CA1334002C (en) 1988-09-28 1995-01-17 Barry D. Sears Essential fatty acid compositions and methods for the modulation of prostaglandin levels in mammals
US6140304A (en) 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
GB8916734D0 (en) * 1989-07-21 1989-09-06 Efamol Holdings Pharmaceutical and dietary uses of fatty acids
GB8918294D0 (en) 1989-08-10 1989-09-20 Efamol Holdings Pharmaceutical compositions
GB8920228D0 (en) 1989-09-07 1989-10-18 Efamol Holdings Fatty acid therapy
JPH04290820A (ja) 1991-03-18 1992-10-15 Idemitsu Petrochem Co Ltd 皮膚病犬の治療方法とその薬剤
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
GB9112052D0 (en) 1991-06-05 1991-07-24 Efamol Holdings Fatty acid treatment
JP3354581B2 (ja) 1991-09-30 2002-12-09 サントリー株式会社 ジホモ−γ−リノレン酸及びこれを含有する脂質の製造方法
GB9211229D0 (en) 1992-05-27 1992-07-08 Efamol Holdings Fatty acid treatment
US5888541A (en) 1992-08-21 1999-03-30 Scotia Holdings Plc Fatty acid treatment
GB9217780D0 (en) 1992-08-21 1992-10-07 Efamol Holdings Fatty acid treatment
FI101039B (fi) 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
DE4238869C2 (de) 1992-11-18 1994-09-08 Wogepharm Gmbh Mittel zur Behandlung des atopischen Ekzems und anderer entzündlicher Hautkrankheiten
GB9301446D0 (en) 1993-01-26 1993-03-17 Scotia Holdings Plc Internal radiation damage
AU683027B2 (en) * 1993-01-27 1997-10-30 Scotia Holdings Plc Triglycerides
CA2119000A1 (en) 1993-03-19 1994-09-20 David Frederick Horrobin Formulation for use in smokers
JPH09505562A (ja) * 1993-10-01 1997-06-03 アール.ピー.シェーラー コーポレイション 香料を小分けして提供する方法および組成物
GB9403855D0 (en) * 1994-03-01 1994-04-20 Scotia Holdings Plc Fatty acid derivatives
US5789441A (en) 1996-02-15 1998-08-04 Virocell Inc. Leukotriene B4 as an antiviral and anti-neoplastic agent
GB9621373D0 (en) 1996-10-14 1996-12-04 Scotia Holdings Plc Fatty acid treatment
GB9710351D0 (en) 1997-05-20 1997-07-16 Scotia Holdings Plc Glucosamine fatty acids
GB9715444D0 (en) 1997-07-22 1997-09-24 Scotia Holdings Plc Therapeutic and dietary compositions
JP2000191525A (ja) 1998-12-25 2000-07-11 Nof Corp 皮膚外用剤組成物
GB9916536D0 (en) 1999-07-14 1999-09-15 Scarista Limited Nutritional or pharmaceutical compositions
EP1072198B1 (de) * 1999-07-28 2008-05-14 SWISS CAPS Rechte und Lizenzen AG Präparat zur Verwendung als Medikament und/oder Nahrungsmittelergänzung
JP4932116B2 (ja) 2000-02-16 2012-05-16 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド アスピリン誘発脂質メディエータ
GB0016045D0 (en) 2000-06-29 2000-08-23 Laxdale Limited Therapeutic combinations of fatty acids
JP2002047176A (ja) * 2000-08-04 2002-02-12 Idemitsu Technofine Co Ltd IgE産生抑制剤
US20020188024A1 (en) 2000-08-23 2002-12-12 Chilton Floyd H. Fatty acid-containing emulsion with increased bioavailability
US20040043013A1 (en) 2000-12-28 2004-03-04 Mccleary Edward Larry Metabolic uncoupling therapy
DE10121252A1 (de) 2001-04-30 2002-11-07 Christos C Zouboulis Behandlung der Akne
SK14502003A3 (en) 2001-05-30 2004-10-05 Laxdale Ltd Coenzyme Q and eicosapentaenoic acid
JP2003155233A (ja) 2001-11-16 2003-05-27 Idemitsu Technofine Co Ltd 塗布剤
AU2003299034A1 (en) 2002-09-20 2004-04-08 Griscom Bettle Iii Transdermal compositions
AU2003284633B2 (en) 2002-11-22 2008-07-10 Nippon Suisan Kaisha, Ltd. External composition containing polyunsaturated fatty acid or its salt or ester
US20050032757A1 (en) * 2003-08-06 2005-02-10 Cho Suk H. Nutritional supplements
JP2005179211A (ja) 2003-12-17 2005-07-07 Idemitsu Kosan Co Ltd 皮膚外用剤組成物
US20070105954A1 (en) 2003-12-31 2007-05-10 Ingennus Limited Formulation containing a carboxylic acid or an ester thereof
BRPI0512864B8 (pt) 2004-07-01 2021-05-25 Johnson & Johnson Vision Care composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
US7666447B2 (en) * 2004-10-08 2010-02-23 Pharmanutrients Compositions including Krill extracts and conjugated linoleic acid and methods of using same
US7893106B2 (en) 2004-11-19 2011-02-22 Martek Biosciences, Corporation Oxylipins from stearidonic acid and γ-linolenic acid and methods of making and using the same
JP5546087B2 (ja) 2005-02-14 2014-07-09 サントリーホールディングス株式会社 皮膚疾患経口治療または予防剤
JP2006306812A (ja) 2005-04-28 2006-11-09 Suntory Ltd 好酸球浸潤抑制剤
WO2006085687A1 (ja) * 2005-02-14 2006-08-17 Suntory Limited ジホモ−γ−リノレン酸(DGLA)を有効成分として含んで成る組成物
US7485323B2 (en) 2005-05-31 2009-02-03 Gelita Ag Process for making a low molecular weight gelatine hydrolysate and gelatine hydrolysate compositions
TW200711649A (en) 2005-06-17 2007-04-01 Combinatorx Inc Combination therapy for the treatment of immunoinflammatory disorders
JP5101894B2 (ja) * 2007-01-15 2012-12-19 サントリーホールディングス株式会社 高度不飽和脂肪酸及びこれを含有する脂質の製造方法
ITMI20070555A1 (it) 2007-03-21 2007-06-20 Giuliani Spa Composizione provvista di attivita' di inibizione sulla 5 alfa-reduttasi
WO2009130291A2 (de) 2008-04-25 2009-10-29 Basf Plant Science Gmbh Pflanzensamenöl
GB0907413D0 (en) 2009-04-29 2009-06-10 Equateq Ltd Novel methods
CA2690488C (en) * 2010-01-19 2013-06-11 Accucaps Industries Limited Pharmaceutical formulations of naproxen for soft gel encapsulation and combinations thereof
GB201001345D0 (en) 2010-01-27 2010-03-17 Equateq Ltd Process for preparing and purifying fatty acids
CA2822263A1 (en) 2010-12-21 2012-06-28 Nestec S.A. Methods and compositions for preventing and treating osteoarthritis
US8293790B2 (en) 2011-10-19 2012-10-23 Dignity Sciences Limited Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof
SG11201401629XA (en) 2011-10-19 2014-05-29 Dignity Sciences Ltd Pharmaceutical compositions comprising dgla and/or 15-hetre and methods of use thereof
SG11201402653QA (en) 2011-11-29 2014-06-27 Dignity Sciences Ltd Compositions comprising 20-carbon fatty acids and methods of making and using same
UA114615C2 (uk) * 2012-01-06 2017-07-10 Омтера Фармасьютікалз, Інк. Збагачена дпк композиція омега-3 поліненасичених жирних кислот у формі вільної кислоти
US20120264705A1 (en) 2012-01-26 2012-10-18 Dignity Sciences Limited Antimicrobial compositions comprising 15-hetre and methods of use thereof
US20130267598A1 (en) 2012-02-23 2013-10-10 Dignity Sciences Limited Pharmaceutical compositions comprising dgla, 15-ohepa, and/or 15-hetre and methods of reducing sebum production using same
EP2833740B1 (en) * 2012-04-04 2016-09-14 Pronova BioPharma Norge AS Compositions comprising omega-3 fatty acids and vitamin d for acne vulgaris and/or eczema, and methods and uses thereof
GB2504061A (en) * 2012-05-25 2014-01-22 Dignity Sciences Ltd Omega-6 Enriched PUFA Phospholipids
WO2014022816A2 (en) 2012-08-03 2014-02-06 Dignity Sciences Limited Pharmaceutical compositions comprising 15-hetre and methods of treating or preventing arthritis using same
GB201216385D0 (en) * 2012-09-13 2012-10-31 Chrysalis Pharma Ag A pharmaceutical composition
ES2784240T3 (es) * 2014-06-04 2020-09-23 Ds Biopharma Ltd Composiciones farmacéuticas que comprenden DGLA y uso de las mismas
CN117402059A (zh) 2015-05-13 2024-01-16 Ds生物制药有限公司 包含15-氧代-epa或15-氧代-dgla的组合物及其制备和使用方法
EP3399971A1 (en) 2016-01-07 2018-11-14 DS Biopharma Limited Pharmaceutical compositions comprising dgla and use of same

Similar Documents

Publication Publication Date Title
JP2020090508A5 (https=)
JP4415243B2 (ja) 脂肪酸の治療効果の増強作用
CN100423718C (zh) 治疗精神性和神经性疾病的高纯乙基epa及其他epa衍生物
AU2002255164A1 (en) Potentiation of therapeutic effects of fatty acids
RU2020101477A (ru) Фармацевтические композиции, содержащие дглк, и их применение
ES2826201T3 (es) Cápsulas entéricas blandas que comprenden ácidos grasos poliinsaturados
JP7132907B2 (ja) ニコチンアミドリボシド及びプテロスチルベン組成物及び神経変性障害の治療方法
JP2004531568A (ja) 補酵素qおよびエイコサペンタエン酸(epa)
JP2008540394A5 (https=)
GB2223943A (en) Oral disage forms of omega-3 polyunsaturated acids
JP2014193924A (ja) オメガ3脂肪酸製剤
JP6313765B2 (ja) 医薬組成物
CZ301307B6 (cs) Použití esenciálních mastných kyselin pro prevenci kardiovaskulárních príhod
JPH11209279A (ja) 体重減少および肥満処置の方法
JP2012513774A (ja) ニトロ脂肪酸を含有する栄養補助物
CN105476020B (zh) 一种维生素d3软胶囊及其制备方法
EP0734723A1 (en) Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
JP2006503031A5 (https=)
CN105343184A (zh) 一种组合物及其应用
US20110217275A1 (en) Compositions comprising probiotic bacteria of the strain bacillus coagulans and omega-3 polyunsaturated fatty acids or derivatives thereof
CN101757624A (zh) 一种预防和治疗老年痴呆症的组合物
CA3072002A1 (en) Methods and compositions for treatment of inflammatory bowel disease
CN117204564B (zh) 一种高生物利用度的水溶性辅酶q10复合载体、制备方法及其应用
US20140335171A1 (en) Stable Formulations of Antiplatelet Agents, Omega-3 Fatty Acids and Amylose In Soft Gelatin Capsules
GB2504061A (en) Omega-6 Enriched PUFA Phospholipids